Innovation and Evolution: A New Myoelectric Upper Limb System by Steeper
1.9.2021 14:07:00 EEST | Business Wire | Press release
In their centenary year Steeper Group, a world leading manufacturer of prosthetic devices, launch their latest myoelectric system. The full limb build is designed to offer patients and clinicians across the globe a durable, high-capacity upper limb system at an affordable cost, which harnesses the power of popular myoelectric technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005522/en/
The Steeper Upper Limb Myoelectric System offers a secure grip via the Myo Kinisi hand, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market. (Photo: Business Wire)
Designed for the everyday, the Steeper Myoelectric System includes the new Myo Kinisi hand which provides an easy to control, high-speed grasp alongside a strong grip force to carry out activities of daily living with ease, with the added benefit of an Auto-Grip function allowing users a more secure grip on difficult to hold objects. The hand is complemented by advanced myoelectrodes for increased accuracy and gain control, and is powered by the all new high-capacity S-Charge System which features a 3500mAh internal battery, making it one of the most powerful available. The prosthesis is finished by the ‘Elegance Plus’ cosmetic glove, designed specifically to complement the Myo Kinisi.
Paul Steeper, CEO of Steeper Group and SteeperUSA commented “a new myoelectric system is something our customers have desired for some time. We’ve used our innovative knowledge of upper limb prostheses to deliver an evolution to a myoelectric system; using the latest advancements in product design, super capacitor technology and modern materials such as titanium for increased strength.”
Patients will enjoy the enhanced cosmesis given by the Elegance Plus silicone glove which has been designed to work in harmony with the Myo Kinisi. An internal reinforced mesh layer increases durability for even high activity users, and improved realism to the skin appearance is achieved with enhancement on the knuckles, joints and nail finish; the Elegance Plus Glove is available in 19 TrueFinishTM shades.
Clinicians can program the Myo Kinisi to meet exacting patient preferences with a choice of five modes and fine adjustments to control parameters can be made via the Steeper Configuration Device, a simple three button operation programming hub with an easy-to-read screen.
Paul Steeper concluded “the Steeper Myoelectric System will offer both clinicians and users a greater choice of durable, reliable and easy to use devices. The Myo Kinisi offers superb grip strength via trusted technology and the Elegance Plus Glove is sure appeal to a wide range of users with its enhanced finish and skin-like texture; couple that with our very latest myoelectrodes and increased capacity S-Charge battery system and users will instantly benefit from these innovations. Patient trials have proved successful with users commenting on the increased control the Myo Kinisi offers whilst using a control strategy they are already familiar with; meaning the hand is easily and readily usable.”
ENDS
Notes to editors:
Steeper Group trade as SteeperUSA within the United States and Canada.
For more information on the Steeper Myoelectric System or any of our upper limb prosthetic products, please visit www.steepergroup.com or www.steeperusa.com.
Image caption: The Steeper Upper Limb Build offers a secure grip, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005522/en/
Contact information
For more information on our centenary celebrations or manufacturing capabilities please contact Frances Beattie, Head of Marketing at: marketingteam@steepergroup.com or call 0113 270 4841.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
SLB Announces Second-Quarter 2026 Results24.7.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas. Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8,721 $8,546 3% 5% Income before taxes - GAAP basis $1,018 $956 $1,285 6% -21% Income before taxes margin - GAAP basis 11.3% 11.0% 15.0% 38 bps -369 bps Net income attributable to SLB - GAAP basis $786 $752 $1,014 5% -22% Diluted EPS - GAAP basis $0.52 $0.50 $0.74 4% -30% Adjusted EBITDA* $1,899 $1,773 $2,051 7% -7% Adjusted EBITDA margin* 21.2% 20.3% 24.0% 83 bps -284 bps Pretax segment operating income* $1,404 $1,321 $1,584 6% -11% Pretax segment operating margin* 15.6% 15.2% 18.5% 49 bps -289 bps Net income attributable to SLB, excluding charges & credits* $833 $783 $1,0
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 13:30:00 EEST | Press release
NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps businesses realize the full value of NIQ's trusted market intelligence by automatically surfacing the trends, opportunities and
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 11:05:00 EEST | Press release
In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-government agreement, funded under the European Union’s SAFE programme, underlines the high level of partnership between France and Romania. The first delivery is expected in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260724603527/en/ The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200MM/A) radars to protect the Romanian airspace. The GM200 MM/A is a combat-proven medium-range 4D AESA radar, already deployed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom